BioInvent International AB (ST:BINV) — Market Cap & Net Worth
Market Cap & Net Worth: BioInvent International AB (BINV)
BioInvent International AB (ST:BINV) has a market capitalization of $158.27 Million (Skr1.47 Billion) as of April 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #18893 globally and #273 in its home market, demonstrating a 1.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioInvent International AB's stock price Skr22.35 by its total outstanding shares 65804362 (65.80 Million).
BioInvent International AB Market Cap History: 2015 to 2026
BioInvent International AB's market capitalization history from 2015 to 2026. Data shows change from $608.73 Million to $158.27 Million (-9.22% CAGR).
BioInvent International AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioInvent International AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.10x
BioInvent International AB's market cap is 6.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $608.73 Million | $15.93 Million | -$90.68 Million | 38.22x | N/A |
| 2016 | $532.54 Million | $71.28 Million | -$62.59 Million | 7.47x | N/A |
| 2017 | $359.07 Million | $45.01 Million | -$100.53 Million | 7.98x | N/A |
| 2018 | $329.93 Million | $38.55 Million | -$123.16 Million | 8.56x | N/A |
| 2019 | $212.55 Million | $93.74 Million | -$139.12 Million | 2.27x | N/A |
| 2020 | $325.05 Million | $147.37 Million | -$76.67 Million | 2.21x | N/A |
| 2021 | $327.17 Million | $19.38 Million | -$278.96 Million | 16.88x | N/A |
| 2022 | $226.97 Million | $326.13 Million | -$34.09 Million | 0.70x | N/A |
| 2023 | $134.27 Million | $71.46 Million | -$330.30 Million | 1.88x | N/A |
| 2024 | $272.64 Million | $44.69 Million | -$429.38 Million | 6.10x | N/A |
Competitor Companies of BINV by Market Capitalization
Companies near BioInvent International AB in the global market cap rankings as of April 19, 2026.
Key companies related to BioInvent International AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #299 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #456 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #457 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #299 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #456 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #457 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
BioInvent International AB Historical Marketcap From 2015 to 2026
Between 2015 and today, BioInvent International AB's market cap moved from $608.73 Million to $ 158.27 Million, with a yearly change of -9.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr158.27 Million | -23.98% |
| 2025 | Skr208.20 Million | -23.64% |
| 2024 | Skr272.64 Million | +103.06% |
| 2023 | Skr134.27 Million | -40.84% |
| 2022 | Skr226.97 Million | -30.63% |
| 2021 | Skr327.17 Million | +0.65% |
| 2020 | Skr325.05 Million | +52.93% |
| 2019 | Skr212.55 Million | -35.58% |
| 2018 | Skr329.93 Million | -8.12% |
| 2017 | Skr359.07 Million | -32.57% |
| 2016 | Skr532.54 Million | -12.52% |
| 2015 | Skr608.73 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of BioInvent International AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $158.27 Million USD |
| MoneyControl | $158.27 Million USD |
| MarketWatch | $158.27 Million USD |
| marketcap.company | $158.27 Million USD |
| Reuters | $158.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more